Pistilli, B., Sohn, J., Schmid, P., Bellet, M., Mastro, L. D., Meisel, J. L., Chan, A., Kermadec, E. D., Zheng, L., McArthur, H. L. (2025). OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps1131